China’s Maccura Biotechnology formed a joint venture with Qiagen of the Netherlands to develop and market Qiagen’s GeneReader NGS system in China. Maccura is a China IVD company. It will own 60% of the JV, which is named Maqgen, while Qiagen will own the rest. Qiagen claims the GeneReader NGS System is the world’s first complete Sample-to-Insight reader and makes NGS available to any laboratory. The JV will focus initially on research use of the machine and broaden that to include Class III hospital networks.
China Med Device, LLC, specializing in providing turn-key solutions for medtech companies entry into China, with services in capital injection, funding partnership, joint venture, merger & acquisition consulting. If you have any feedback on this post or would like to know more of our services, please email us at info@ChinaMedDevice.com or visit us at www.ChinaMedDevice.com.